Discover Cutting-Edge Solutions with Xentria Inc.

Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet medical needs, ... Xentria ... Focused on becoming a critical leader in the biopharma industry through a strong portfolio of products having purpose for patients. Driven to treat ... Xentria Inc., a Chicago-based biotech company, opened its new corporate headquarters in Lincoln Park this week. The company also secured a ... CHICAGO, Dec. 19, 2024 /PRNewswire/ -- Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development ... The Xentria trial is a Phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis. See below for information about the trial sites for this clinical ... ... Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was established in April 2020. Victoria came to Meitheal from Sagent ... Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million. Xentria is a biotech company building authentic life-sciences partnerships to guide innovative drug and intellectual property development from early ... Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their ... Vice President, Clinical Development - Xentria, Inc. · Solutions-focused clinical development professional with a diverse background in patient care, ...